Guidance, NICE advice and quality standards in development | Guidance

Showing 21 to 30 of 370

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure: Early Value Assessment	Health technology evaluation	19 May 2026
Artificial intelligence software to help detect and characterise colorectal polyps	Diagnostics guidance	5 March 2026
Artificial intelligence-based technologies to aid lung function measurement for the diagnosis of suspected lung conditions: Early Value Assessment	Health technology evaluation	2 April 2026
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]	Technology appraisal guidance	TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]	Technology appraisal guidance	TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]	Technology appraisal guidance	TBC